VBI Vaccines (VBIV) Shares Down 5.4%

VBI Vaccines Inc (NASDAQ:VBIV) was down 5.4% during trading on Thursday . The stock traded as low as $2.08 and last traded at $2.12. Approximately 574,982 shares traded hands during trading, an increase of 165% from the average daily volume of 216,720 shares. The stock had previously closed at $2.24.

Several equities research analysts have recently commented on VBIV shares. Zacks Investment Research upgraded VBI Vaccines from a “sell” rating to a “hold” rating in a report on Thursday, July 26th. BMO Capital Markets decreased their price objective on VBI Vaccines from $13.00 to $12.00 and set an “outperform” rating for the company in a report on Friday, July 27th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. VBI Vaccines has a consensus rating of “Hold” and an average price target of $9.08.

The company has a debt-to-equity ratio of 0.14, a current ratio of 2.75 and a quick ratio of 2.69.

VBI Vaccines (NASDAQ:VBIV) last released its quarterly earnings data on Thursday, July 26th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.09). The firm had revenue of $0.23 million for the quarter. VBI Vaccines had a negative net margin of 6,175.95% and a negative return on equity of 53.12%. On average, equities research analysts forecast that VBI Vaccines Inc will post -0.94 EPS for the current year.

In other news, CEO Jeff Baxter acquired 16,800 shares of the firm’s stock in a transaction dated Tuesday, July 31st. The stock was purchased at an average price of $2.28 per share, for a total transaction of $38,304.00. Following the completion of the acquisition, the chief executive officer now directly owns 211,405 shares in the company, valued at approximately $482,003.40. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. In the last 90 days, insiders have bought 40,400 shares of company stock valued at $85,092. Corporate insiders own 16.20% of the company’s stock.

Several large investors have recently made changes to their positions in VBIV. Russell Investments Group Ltd. boosted its position in shares of VBI Vaccines by 7.3% during the first quarter. Russell Investments Group Ltd. now owns 491,449 shares of the biopharmaceutical company’s stock valued at $1,720,000 after buying an additional 33,588 shares during the last quarter. Menora Mivtachim Holdings LTD. boosted its position in shares of VBI Vaccines by 2.3% during the first quarter. Menora Mivtachim Holdings LTD. now owns 2,715,162 shares of the biopharmaceutical company’s stock valued at $9,503,000 after buying an additional 61,203 shares during the last quarter. General American Investors Co. Inc. boosted its position in shares of VBI Vaccines by 44.1% during the second quarter. General American Investors Co. Inc. now owns 864,464 shares of the biopharmaceutical company’s stock valued at $2,377,000 after buying an additional 264,464 shares during the last quarter. LMR Partners LLP purchased a new position in shares of VBI Vaccines during the second quarter valued at approximately $233,000. Finally, Dimensional Fund Advisors LP purchased a new position in shares of VBI Vaccines during the second quarter valued at approximately $223,000. 47.99% of the stock is currently owned by institutional investors.

About VBI Vaccines (NASDAQ:VBIV)

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus.

Further Reading: What is the yield curve?

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply